Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Mechanistic diagram of P2Y 14 R.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Representative chemical structures of known P2Y 14 R antagonists.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Structural superposition of the five P2Y 14 R complexes.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Distribution of docking scores between known antagonists and decoy compounds using SP and XP scoring modes of Glide docking for five P2Y 14 R complexes.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using DrugRep.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: Docking poses and chemical structures of (a) the top10 FDA approved drugs (b) the top10 FDA experimental drugs predicted as potential P2Y 14 R antagonists using Glide XP docking and MM/GBSA minimizations.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The potential P2Y 14 R antagonists with the highest ranking from DrugBank, which include both approved and experimental drugs, were predicted using (a) AutoDock Vina of DrugRep and (b) Glide XP docking followed by MM/GBSA minimizations.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: (a) Per-residue interaction decomposition of the antagonist-P2Y 14 R binding free energy for P2Y 14 R· 7 and P2Y 14 R· DB07565 . (b) The 3D-cocrystal structure of P2Y 14 R with DB07565 . (c) Schematic representation of the GPCR-membrane complex.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques: Residue, Binding Assay, Membrane

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The DCCM analysis of apo and antagonistic P2Y 14 R system.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The free energy landscape analysis of apo-P2Y 14 R system and corresponding conformation in local energy minima.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The free energy landscape analysis of (a) P2Y 14 R· 7 and (b) P2Y 14 R· DB07565 system and corresponding conformations in local energy minima.

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques:

Journal: Journal of Advanced Research

Article Title: Computational discovery and repurposing of chloramphenicol succinate as a potent P2Y 14 receptor antagonist for inflammatory bowel disease therapy

doi: 10.1016/j.jare.2025.08.035

Figure Lengend Snippet: The in vitro biological testing of DB07565 . (a) In vitro P2Y 14 R antagonistic activity of DB07565 (N = 3). (b) The effect of DB07565 on cell viability of HT-29 cells (N = 5).

Article Snippet: Human embryonic kidney 293 (HEK293) cells, which stably express the human P2Y 14 receptor (hP2Y 14 -HEK293 cells), were obtained from Keygen Biotech Co., Ltd.

Techniques: In Vitro, Activity Assay

Journal: Frontiers in Immunology

Article Title: Multi-omics insights into immune tolerance at the maternal–fetal interface in recurrent pregnancy loss: mechanisms, integration challenges, and translational perspectives

doi: 10.3389/fimmu.2026.1811970

Figure Lengend Snippet: Disrupted cellular interaction network at the maternal–fetal interface in recurrent pregnancy loss (RPL). This schematic illustrates representative alterations in cell–cell communication associated with immune tolerance failure at the maternal–fetal interface. Under pathological conditions, impaired decidual stromal cell (DSC)-derived transforming growth factor-β (TGF-β) signaling may contribute to loss of the tolerogenic uterine natural killer (uNK) cell phenotype. Reduced Galectin-9 signaling and abnormal uNK–human leukocyte antigen-C (HLA-C)/killer immunoglobulin-like receptor (KIR) interactions may weaken trophoblast support. In parallel, macrophage polarization may shift toward a pro-inflammatory M1-like state, and the balance between regulatory T cells (Treg) and T helper 17 (Th17) cells may become disrupted. These alterations are associated with impaired trophoblast support and increased susceptibility to trophoblast stress and apoptosis. This figure is intended as a conceptual summary of reported cellular interaction abnormalities rather than a definitive mechanistic model. DSCs, decidual stromal cells; FASL, Fas ligand; HLA-C, human leukocyte antigen-C; KIR, killer cell immunoglobulin-like receptor; TGF-β, transforming growth factor-β; Th17, T helper 17 cells; TNFRs, tumor necrosis factor receptors; Treg, regulatory T cells; uNK, uterine natural killer cell.

Article Snippet: Furthermore, abnormal uNK–trophoblast interactions have been associated with reduced Galectin-9 expression and imbalanced killer immunoglobulin-like receptor (KIR)–human leukocyte antigen-C (HLA-C) pairing, which may impair trophoblast invasiveness and endothelial remodeling, ultimately contributing to defective spiral artery remodeling and placental perfusion disorders ( , ).

Techniques: Derivative Assay